Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a ...

Hikma Pharmaceuticals Plc reached a $50 million deal to settle claims it colluded with other drugmakers to delay the generic version of brand-name narcolepsy drug Xyrem.

Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday announced it has reached a settlement deal for up to USD50 million in cash for litigation brought against the firm in relation to its narcolepsy ...

Jazz Pharmaceuticals JAZZ reported first-quarter 2025 adjusted earnings of $1.68 per share, which significantly missed the ...

Jazz Pharmaceuticals PLC (JAZZ) reports robust Q1 2025 performance with significant revenue growth in neuroscience, despite a ...

Jazz Pharmaceuticals ( NASDAQ: JAZZ) shares fell after the market on Tuesday as the company lowered its full year bottom-line expectation, to reflect the impact of the Chimerix deal and certain Xyrem ...

As with other drugs, Xyrem (sodium oxybate) can cause side effects, such as nausea, vomiting, and dizziness. If side effects of Xyrem become difficult to tolerate, talk with your doctor or pharmacist.

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. Early this week ...

Subject to court approval, the settlement will bring an end to class action lawsuits initiated by several Xyrem buyers who accused Ireland-based Jazz (NASDAQ:JAZZ) of reaching illegal patent ...

A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England. But are there any alternatives? asks Leela Barham. The National ...